Earnings Estimates: Analysts forecast an EPS of $3.82 for the upcoming quarter, indicating a 32% year-over-year decline. Revenue is projected at $44.67 billion, a 5.2% increase from the same period last year.
Oversold Potential: With an oversold score of 59%, ELV appears attractive for accumulation.
PEG Ratio: The PEG ratio stands at -0.77, suggesting undervaluation despite negative growth.
Valuation Metrics: A forward P/E of 11.03, lower than the trailing P/E of 14.14, indicates potential undervaluation.
Revenue Growth: Positive quarterly revenue growth estimates point to resilient performance.
In the previous quarter, Elevance reported an EPS of $8.37, missing the consensus estimate of $9.66, but achieved a 5.3% year-over-year revenue increase to $44.72 billion.
Guidance: In the previous quarter, Elevance Health revised its full-year 2024 adjusted EPS guidance downward to approximately $33, down from the prior estimate of $37.20, due to challenges in its Medicaid business.
Despite these hurdles, Elevance's diversified portfolio and strategic initiatives position it for potential growth.
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.
Tracking chart Setups like meteorologist track Storms.
Juga di:
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.